Abstract. Fluorouracil (5-Fu) and 5-azacitidine (5-aza) are two types of nucleoside analog, which have been widely applied in the treatment of several types of cancer. However, the effect of these two types of drug on the proliferation and DNA methylation of cancer cells has not been compared in a single study. In the present study, in vitro cultured human gastric cancer cells (hGCCs) were treated with various concentrations of 5-Fu and 5-aza, and cell counting, MTT assay and methyl-sensitive amplified polymorphism were used to evaluate the resulting levels of proliferation and DNA methylation of hGCCs. The results revealed that the two drugs were able to inhibit the proliferation of hGCCs, but that the effect of 5-aza was weaker than that of 5-Fu. However, 5-aza decreased the level of DNA methylation in hGCCs, whereas 5-Fu did not alter DNA methylation. These results indicated that 5-Fu was able to more efficiently inhibit the proliferation of hGCCs than 5-aza, and that this difference may be due to differences in the anticancer mechanism of these two types of drug.
Introduction
Cancer, also known as malignant tumor, represents a significant threat to human health. Tumorigenesis occurs as a result of the activation of oncogenic pathways and/or inactivation of tumor suppressor pathways (1) . Changes in the DNA sequence, including mutations, amplifications, gene rearrangements or deletions, were hypothesized to underlie tumorigenesis (2); however, aberrant epigenetic modifications also have a important role in cancer occurrence and progression. For example, DNA methylation, a type of epigenetic modification, was found to exhibit a distorted pattern in human cancer cells (3) . Hypomethylation of intergenic regions and hypermethylation within the promoter regions of numerous CpG island-associated tumor suppressor genes has been observed in cancer cells (4, 5) . Hypomethylation of intergenic regions may result in the activation of transposable elements and instability of the genome in cancer cells (6) , while hypermethylation of promoter regions may result in the silencing of tumor suppressor genes and uncontrolled cancer cell proliferation (7) . Therefore, various types of DNA methyltransferase inhibitors have been used in cancer therapies (8) . Fluorouracil (5-Fu) and 5-azacitidine (5-aza), two types of nucleoside analog, have been used to treat several types of cancer (8, 9) . However, the anticancer mechanisms underlying the effects of these two types of drug are distinct. Firstly, 5-aza is a type of DNA methyltransferase inhibitor, which is incorporated into DNA, leading to inhibition of DNA methylation and restoration of the expression of silenced tumor suppressor genes (10, 11) . By contrast, 5-Fu is a type of antimetabolite drug, which inhibits essential biosynthetic processes via incorporation into DNA and RNA, consequently inhibiting the normal function of these macromolecules in cancer cells (9) . Although these two types of drug have been widely applied to treat various types of cancer, their effects on the proliferation and DNA methylation of cancer cells have not previously been compared in a single study.
In the present study, in vitro cultured human gastric cancer cells (hGCCs) were studied, following treatment with various concentrations of 5-Fu or 5-aza. The effects of these two types of drug on the proliferation and DNA methylation of hGCCs, as well as their underlying mechanisms, were investigated by cell counting, MTT assay and methyl-sensitive amplified polymorphism (MSAP).
Materials and methods
Reagents. Unless otherwise indicated, all chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). Cell counting. Following 24 h of treatment with 5-Fu or 5-aza, the proliferation of hGCCs was evaluated by cell counting. Briefly, hGCCs were removed by digestion medium, dyed with 0.4% (m/v) trypan blue medium (trypan blue was supplemented into RPMI-1640 complete medium) for 3 min and mounted on an inverted microscope (Eclipse Ti-U; Nikon Corporation, Tokyo, Japan) for living cell counting. Cell counting was performed every 24 h from day 1 (following 24 h of drug treatment) to day 7. Each treatment, as well as the controls (cultured in RPMI-1640 complete medium alone), was repeated 3 times.
MTT assay. On days 3 and 6, the proliferation inhibition of hGCCs was evaluated by MTT assay. Briefly, MTT solution [MTT dissolved in phosphate-buffered saline (PBS)] was added into each well at a final concentration of 200 mg/l. Subsequently, plates were incubated in identical conditions to those described above for 3 h. Following removal of the supernatant, 150 µl dimethyl sulfoxide was added to each well, plates were slightly oscillated for 10 min and the absorbance (A) of each well at 490 nm was recorded using a Microplate Reader (Synergy HT; BioTek Instruments, Inc., Winooski, VT, USA). Each treatment, as well as the control, was repeated 4 times.
Extraction of genomic DNA from hGCCs. On day 3, hGCCs were removed by digestion medium and washed 2-3 times in PBS medium prior to genomic DNA extraction using a cell genome DNA extraction kit (TianGen Biochemistry Technology Co., Ltd, Beijing, China) according to the manufacturer's instructions, and stored at -20˚C for subsequent experiments. Two adaptors were designed as described previously (12) . These were HapII/MspI (H-M) adaptor:
H-M( I ), 5'-GACGATGTCTAGA A-3' a nd H-M( I I ), 5'-CGTTCTAGACTCATC-3'; and EcoRI (E) adaptor: E(I), 5'-CTCGTAGACTGCGTACC-3' and E(II), 5'-AATTGG-TACGCAGTCTAC-3'. The connection mixture consisted of 12.5 µl digestion product, 5 µl (10 pmol) H-M adaptor, 5 µl (10 pmol) E adaptor, 3 µl T4 DNA ligase, 5 µl 10X connection buffer and 19.5 µl ddH 2 O in a total volume of 50 µl. Connections were performed at 16˚C overnight, prior to inactivation of T4 DNA ligase (Takara Biotechnology Co., Ltd., Dalian, China), at 65˚C for 8 min. Subsequently, the connection product was stored at -20˚C for subsequent experiments.
A pair of primers was designed for the pre-polymerase chain reaction (PCR), as described previously (12) , which were as follows: Forward, 5'-GATGAGTCTAGAACGGT-3' and reverse, 5'-GACTGCGTACCAATTCA-3'. The pre-PCR reaction mixture consisted of 0.5 µl connection product, 1 µl forward primer (30 ng/µl), 1 µl reverse primer (30 ng/µl), 1.6 µl dNTPs (2.5 mM each; Takara Biotechnology Co., Ltd.), 1.2 µl MgCl 2 (25 mM), 1 µl rTaq (5 U/µl; Takara Biotechnology Co., Ltd.), 2 µl 10X rTaq buffer and 11.7 µl ddH 2 O, in a total volume of 20 µl. Pre-PCR was performed as follows: Holding at 94˚C for 5 min, then 30 cycles of denaturation at 94˚C for 30 sec, annealing at 56˚C for 1 min and extension at 72˚C for 1 min, followed by a final extension at 72˚C for 7 min. The PCR products were loaded onto 0.8% agarose gel for electrophoresis and stained with ethidium bromide.
The primers used for selective amplification were as follows: Forward, 5'-GATGAGTCTAGAACGGTNN-3' and reverse, 5'-GACTGCGTACCAATTCANN-3', where N was any one of the A, T, C or G nucleotides. In the present study, 5 forward primers (5'-GATGAGTCTAGAACGGTGC-3', 5'-GATGAGTCTAGAACGGTAT-3', 5'-GATGAGTCTAGA ACGGTCA-3', 5'-GATGAGTCTAGAACGGTTC-3' and 5'-GATGAGTCTAGAACGGTAG-3) and 5 reverse primers (5'-GACTGCGTACCAATTCACT-3', 5'-GACTGCGTACCA ATTCAAG-3', 5'-GACTGCGTACCAATTCATA-3', 5'-GAC TGCGTACCAATTCAGT-3' and 5'-GACTGCGTACCA ATTCAAC-3') were randomly matched, so that a total of 25 pairs were used. The selective amplification reaction mixture consisted of 0.2 µl pre-PCR products, 1 µl forward primer (30 ng/µl), 1 µl reverse primer (30 ng/µl), 1.6 µl dNTPs (2.5 mM each), 1.2 µl MgCl 2 (25 mM), 0.5 µl rTaq (5 U/µl), 2 µl 10X rTaq buffer and 12.5 µl ddH 2 O in a total volume of 20 µl. Selective amplification was performed under the following conditions: Holding at 94˚C for 5 min, then 13 cycles of denaturation at 94˚C for 30 sec, annealing at 65˚C (each cycle decreased by 0.7˚C) for 30 sec and extension at 72˚C for 1 min, followed by 23 cycles of denaturation at 94˚C for 30 sec, annealing at 56˚C for 30 sec and extension at 72˚C for 1 min, and further extension at 72˚C for 7 min. The PCR products were loaded onto 10% polyacrylamide gel for electrophoresis and stained with silver nitrate, then developed with 1.5% (w/v) sodium hydroxide and 0.4% (v/v) formaldehyde.
Statistical analysis. Differences in the proliferation and proliferation inhibition of hGCCs were statistically compared by one-way and two-way analysis of variance, respectively. As indicated in Fig. 1 , following treatment with various concentrations of 5-Fu, the hGCCs began to die from day 1 to 7, whereas untreated hGCCs were able to proliferate continuously during this period. The difference in the number of living cells between the untreated and 5-Fu-treated groups was significant (P<0.05) from day 1 to 7; however, this difference was not significant (P>0.05) among the 5-Fu-treated groups.
In addition, following treatment with various concentrations of 5-aza, hGCCs remained able to proliferate; however, compared with that of the untreated group, the proliferation rate of the 5-aza-treated groups was markedly slower, and the difference in the number of living cells between the untreated and 5-aza-treated groups was significant on days 4-7 (P<0.05). Furthermore, significant differences among each 5-aza-treated group appeared on day 5 and lasted to day 7 (P<0.05). However, on day 7, the difference between the 10 and 15 µmol/l group was not significant (P>0.05; Fig. 2 ).
Proliferation of hGCCs is inhibited following treatment with 5-Fu or 5-aza.
Following 3 and 6 days of treatment with various concentrations of 5-Fu or 5-aza, the inhibition of hGCC proliferation was measured by MTT assay and calculated using the following formula: Cell proliferation inhibition rate (%)=[1-A490(experimental group)/A490(control group)] x100, as described previously (11) .
As shown in Fig. 3 , 5-Fu effectively inhibited the proliferation of hGCCs, and the inhibition rate was time-dependent, but not concentration-dependent from 10 to 40 g/l, as no significant differences in inhibition rate were observed among the various treatment groups. The proliferation of hGCCs was also inhibited by 5-aza treatment, and the inhibition rate was time-and concentration-dependent. However, compared with 5-Fu, the inhibitory effect of 5-aza on the proliferation of hGCCs was weaker. These results were in accordance with the results of the living cell counting assay.
Treatment with 5-aza decreases DNA methylation levels in hGCCs.
Following 3 days of treatment with various concentrations of 5-Fu or 5-aza, the levels of DNA methylation were measured by MSAP assay.
As shown in Fig. 4 , the products of selective amplification were run on polyacrylamide gel, and each sample of hGCCs genomic DNA displayed an H lane and an M lane, which corresponded to the products of EcoRI/HapII and EcoRI/MspI digestion, respectively. The number of bands in the pairs of lanes indicated the quantity of products of genomic DNA samples amplified by each pair of primers. The bands could be divided into three types. If the band was detected in the H and M lane, this band represented a non-methylated site (I ; Fig. 4) ; if the band presented only in the H lane, this band represented a hemimethylated site (II ; Fig. 4) ; and if the band presented only in the M lane this band represented a methylated site (III ; Fig. 4 ). The number of bands amplified by all the pairs of primers was counted, and the levels of methylation, hemimethylation and total methylation were calculated according to the following formulae:
Level of hemimethylation = (number of hemimethylated bands)/(total number of bands)
Level of methylation = (number of methylated bands)/(total number of bands).
As indicated in Table I , following 3 days of treatment with various concentrations of 5-Fu, the levels of methylation and hemimethylation in hGCC genomic DNA were not significantly altered (P>0.05). This result indicated that 5-Fu was unable to markedly alter the level of DNA methylation in the hGCC genome. However, following 3 days of treatment with various concentrations of 5-aza, the levels of DNA methylation and hemimethylation in the hGCC genome were significantly decreased (P<0.05), compared with those of the untreated group, and the differences were not significant amongst each of the 5-aza treatment groups (P>0.05).
Discussion
In the present study, the effects of two nucleoside antitumor drugs, 5-Fu and 5-aza, on the proliferation of hGCCs were investigated. The results of living cell counting and MTT assay revealed that 5-Fu more efficiently inhibited the proliferation of hGCCs than 5-aza. This may be due to differences in the anticancer mechanism of these two types of drug. 5-Fu is an antimetabolite drug, which may be intracellularly converted into several active metabolites. These metabolites are able to form a stable ternary complex with thymidylate synthase and 5,10-methylenetetrahydrofolate, or misincorporate into DNA and RNA, disrupting DNA synthesis and repair or RNA processing and function (9) . Therefore, 5-Fu exerts lethal effects on cancer cells only in a single cell cycle. By contrast, 5-aza is a type of DNA methyltransferase inhibitor, which is able to induce degradation of DNA methyltransferase 1 (DNMT1), resulting in DNA demethylation and the re-expression of certain silenced tumor suppressor genes, as well as inhibiting the proliferation of cancer cells (11, 13) . Therefore, 5-aza is able to inhibit the uncontrolled proliferation of cancer cells through multiple cell cycles, which explains why the inhibitory effect of 5-aza on the proliferation of hGCCs was weaker than that of 5-Fu in the present study. Previous studies have indicated that following treatment of cancer cells with 5-aza, certain tumor suppressor genes, including p16, DAPK, MGMT, FHIT, CDKN2B, ESR1 and IGSF4, exhibited DNA demethylation and were subsequently re-expressed (11,13); however, changes in the levels of DNA methylation at the genome scale were not examined in these studies. In the present study, an MSAP assay was performed to examine the levels of DNA methylation in the hGCC genome. The results revealed that 5-aza was able to significantly decrease the levels of DNA methylation and hemimethylation in the hGCC genome, whereas 5-Fu was not. This result was consistent with the differences in the anticancer mechanism of these two types of drugs, and indicated that 5-aza was able to decrease the activity of DNMT1, a type of maintenance methyltransferase, which methylates hemimethylated DNA strands following S phase. MSAP technology may be used to test the genome-wide levels of DNA methylation, particularly when sequence information for the genome is unavailable. This technology is reliable, inexpensive and relatively simple, therefore MSAP has been widely used to analyze DNA methylation changes in plants and animals (14) (15) (16) . Recently, MSAP technology was used to successfully examine the level of DNA methylation of sheep cloned embryos at various development stages (12) .
In conclusion, the two types of nucleoside antitumor drug, 5-Fu and 5-aza, inhibited the proliferation of hGCCs; however, 5-Fu was more efficient than 5-aza. In addition, 5-aza was able to decrease the levels of DNA methylation in the hGCC genome, whereas 5-Fu was not. These results reflect the distinct effects and mechanisms of these two types of drug on the proliferation of hGCCs. Although epigenetic therapy was previously highly recommended to treat cancer, the results of the present study indicate that the slow effect of this type of treatment should be taken into consideration. Instead, it is proposed that a combination of metabolic and epigenetic treatment may be a more favorable therapeutic strategy.
